According to the research report titled ‘Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global idiopathic pulmonary fibrosis market was valued at USD 3271.3 million in 2020 and is projected to showcase robust growth through 2021-2026.

The increasing use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands, the rising prevalence of fibrotic disease, and the growing geriatric population is some of the chief factors stimulating the expansion of global idiopathic pulmonary fibrosis market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489502/  

For the unversed, various non-pharmacological treatments are employed for IPF patients in addition to pharmacological ones. Lung transplants, oxygen therapy, mechanical ventilation, and pulmonary rehabilitation are the non-pharmacological treatments that are most frequently employed. The main treatment strategy for IPF is largely influenced by the patient's symptoms, the disease's stage, and their general health.

Apart from this, surging demand for cost-effective drugs, the introduction of advanced treatment options, changing lifestyle patterns, increasing consumption of nicotine products, rising development of IPF due to excessive smoking of tobacco and cigarettes, and growing health awareness among the masses regarding IPD management will add traction to the overall market growth.

Additionally, the advent of novel medicines, advancements in the IPF diagnostic and treatment methods, extensive research & development activities, and improvements in the healthcare infrastructure are expected to propel the overall industry size.

Based on the drug type, this business arena is divided into pirfenidone, nintedanib, and others. With respect to the end-user terrain, worldwide idiopathic pulmonary fibrosis market is split into academic and research organizations, hospitals & clinics, and others.

The geographical scope of this marketplace extends to the Asia Pacific, Europe, and North America, with major emphasis on countries such as China, Japan, France, the U.K., Germany, the U.S., Canada, Italy, India, and Spain. Among these, North America is currently leading in terms of market share and is likely to depict similar growth trends in the forthcoming years.

The prominent companies operating in global idiopathic pulmonary fibrosis market are MediciNova Inc., FibroGen, Inc., Galapagos NV, Cipla Limited, Liminal BioSciences Inc., Gilead Sciences Inc., The Merck Group, C.H. Boehringer Sohn Ko. KG, F. Hoffmann-La Roche AG, The Bristol-Myers Squibb Company, and AbbVie Inc.